Pharma

Your Article Summary

See Latest Articles

AVI BioPharma to Present Safety Data in Duchenne Muscular Dystrophy at 14th Annual International Congress of the World Muscle Society
AVI BioPharma, 08/27/09

AVI BioPharma, Inc. , a developer of RNA–based drugs, announced that it will present the full data from its completed Phase 1 clinical trial of its splice skipping oligomer AVI–4658 in patients with Duchenne Muscular Dystrophy at the 14th Annual International Congress of the World Muscle Society on Saturday, September 2009 in Geneva, Switzerland.

Today in Conferences/Meetings...keeping you current

Receive free subspecialty "5-minute updates" via email

Covidien plc to Report First-Quarter Results on January 2010
Covidien, 12/17/09

ONC to Explain Community I.T. Project
HealthDataManagement, 12/17/09

MediGene AG presents future business plan at annual analyst conference
MediGene, 12/16/09

 See all of Conferences/Meetings